POSTER SESSION 4

Tuesday June 14, 2016: 12:45-14:15
Exhibition Space (30 Euston Square)

PS4

PS4-1

Durda Vukicevic, MD, UMIT - University for Health Sciences, Medical Informatics and Technology, Institute of Public Health, Medical Decision Making and Health Technology Assessment, Department of Public Health, Health Services Research and Health Technology Assessment, Hall in Tyrol, Austria, Ursula Rochau, MD, MSc, UMIT - University for Health Sciences, Medical Informatics and Technology, Institute of Public Health, Medical Decision Making and HTA, Department of Public Health and HTA/ ONCOTYROL - Center for Personalized Cancer Medicine, Area 4 HTA and Bioinformatics, Hall in Tyrol/ Innsbruck, Austria, Aleksandar Savic, MD, PhD, Clinic for hematology, Clinical Center of Vojvodina, Medical Faculty, University of Novi Sad, Novi Sad, Serbia, Monika Buchberger, MSc, UMIT - University for Health Sciences, Medical Informatics and Technology, Institute of Public Health, Medical Decision Making and Health Technology Assessment, Department of Public Health, Health Services Research and Health Technology Assessment, Hall i.T., Austria, Milica Jevdjevic, DMD, Institute of Public Health, Medical Decision Making and Health Technology Assessment, Department of Public Health, Health Services Research and Health Technology Assessment, UMIT - University for Health Sciences, Medical Informatics and Technology, Hall i. T., Austria, Gaby Sroczynski, MPH, Dr.PH, UMIT - University for Health Sciences, Medical Informatics and Technology, Institute of Public Health, Medical Decision Making and HTA, Department of Public Health, Health Services Research and HTA/ ONCOTYROL - Area 4, HTA and Bioinformatics, Hall i.T./Innsbruck, Austria and Uwe Siebert, MD, MPH, MSc, ScD, UMIT, Hall in Tirol (Austria) / Boston (USA), Austria
PS4-2

Elisabeth Adams1, Rebecca Glover1, Andres Vecino Ortiz1, Sam Douthwaite2 and Simon Goldenberg2, (1)Aquarius Population Health, London, United Kingdom, (2)Guy's and St Thomas' NHS Trust, London, United Kingdom
PS4-3

Beate Jahn, PhD1, Gaby Sroczynski, MPH, Dr.PH1, Annette Conrads-Frank, PhD1, Gregoire Jeanblanc, MD2, Aurore Duguet, PharmD2, Derek Misurski, PhD3, Jennifer Samp, PHARMD, MS3 and Uwe Siebert, MD, MPH, MSc, ScD4, (1)Department of Public Health, Health Services Research and Health Technology Assessment, UMIT - University for Health Sciences, Medical Informatics and Technology, Hall i.T., Austria, (2)AbbVie Inc., Rungis, France, (3)AbbVie Inc., North Chicago, IL, (4)UMIT, Dept. of Public Health, Health Services Research and Health Technology, Hall in Tirol, Austria
PS4-4

Fan Yang, PhD1, Brenda Gannon, PhD1 and Nan Luo, PhD2, (1)Manchester Centre for Health Economics, University of Manchester, Manchester, United Kingdom, (2)Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore
PS4-5

Mike Paulden, MA., MSc., University of Alberta, Edmonton, AB, Canada and Christopher McCabe, PhD, Department of Emergency Medicine, University of Alberta, Edmonton, AB, Canada
PS4-6

Teresa Gavaruzzi1, Alessandra Tasso2, Marzena Franiuk3, Liliana Varesco3 and Lorella Lotto1, (1)DPSS, University of Padova, Padova, Italy, (2)University of Ferrara, Ferrara, Italy, (3)IRCCS AOU San Martino, Genova, Italy
PS4-7

Marieke G.M. Weernink, MSc1, Marije van der Straten, MSc1, Paul J.M. Kil, MD, PhD2, Jeroen P.P. van Vugt, PhD3, Maarten J. IJzerman, PhD1 and Janine A. van Til, PhD1, (1)University of Twente, Enschede, Netherlands, (2)St. Elisabeth Hospital, Tilburg, Netherlands, (3)Department of Neurology, Medical Spectrum Twente, Enschede, Netherlands
PS4-8

Gopikrishnan Mannamparambil Chandrasekharan, B.D.S, M.Sc, Dympna O'Sullivan, PhD and Andrew MacFarlane, PhD, City University London, London, United Kingdom
PS4-10

Alice Forster, BSc, MSc, PhD1, Lauren Rockliffe, BSc, MSc1, Amanda Chorley, BSc, MSc1, Laura Marlow, BSc, MSc, PhD1, Helen Bedford, RGN, BSc, MSc, PhD1, Samuel Smith, BSc, MSc, PhD2 and Jo Waller, BA, MSc, PhD1, (1)UCL, London, United Kingdom, (2)Queen Mary University of London, London, United Kingdom
PS4-11

Juan Carlos Aviles Solis, MD, General Practice Reseach Unit, TromsoŞ, Norway, Peder A. Halvorsen, MD, PhD, Department of Community Medicine, UiT - The Arctic University of Norway, Troms°, Norway and Hasse Melbye, MD, PhD, General Practice Reseach Unit, Tromso, Norway
PS4-12

Yukari Yamamoto, RN, MPH, Shiho Urakawa, MD, MA and Yoshiyuki Takimoto, MD, Ph.D, The University of Tokyo, Tokyo, Japan
PS4-13

Bj÷rn Stollenwerk, PhD1, Andrew Briggs, DPhil2, Bastian Dehmel, MD3, Ron Akehurst, BSc (Econ) (London), Hon MFPHM4, Patrick Parfrey, MD, FRCPC, OC, FRSC5, Sergio Iannazzo, PhD6, Michael Adena, PhD7 and Vasily Belozeroff, PhD3, (1)Amgen (Europe) GmbH, Zug, Switzerland, (2)University of Glasgow, Glasgow, United Kingdom, (3)Amgen Inc., Thousand Oaks, CA, (4)BresMed, Sheffield, United Kingdom, (5)Memorial University, St. John's, NF, Canada, (6)SIHS Health Economics Consulting, Torino, Italy, (7)Datalytics Pty Ltd, Bruce ACT, Australia
PS4-14

Valeria E. Rac, MD, PhD1, Yeva Sahakyan, MD, MPH2, Nida Shahid, HBSc., MSc (c.)2, Aleksandra Stanimirovic, MSc, PhD (candidate)2, Iris Fan, BA1, Welson Ryan2 and Murray D. Krahn, MD, MSc3, (1)Toronto Health Economics and Technology Assessment (THETA) Collaborative, Toronto, ON, Canada, (2)Toronto Health Economics and Technology Assessment (THETA) Collaborative, University of Toronto, Toronto, ON, Canada, (3)University of Toronto and University Health Network, Toronto General Research Institute, Toronto Health Economics and Technology Assessment (THETA) Collaborative, Toronto, ON, Canada
PS4-15

Niki Popper, PhD, dwh Simulation Services /Technical University Vienna, Institute for Analysis and Scientific Computing / DEXHELPP (Decision Support for Health Policy and Planning), Vienna, Austria, Barbara Glock, MSc, dwh Simulation Services, Wien, Austria, Matthias Schauppenlehner, Mag., Main Association of Social Insurances, Vienna, Austria and Harald Piringer, Dr., VRVis Zentrum fuer Virtual Reality und Visualisierung Forschungs-GmbH, Vienna, Austria
PS4-16

Jeffrey Wale, LLB (Hons); PGCE, Bournemouth University, Poole, United Kingdom of Great Britain and Northern Ireland
PS4-17

Kate Mandeville1, Benjamin Cooper2, Sian Martin2, Mylene Lagarde1, Stian Reimers2 and Kielan Yarrow2, (1)London School of Hygiene and Tropical Medicine, London, United Kingdom, (2)City University London, London, United Kingdom
PS4-18

Simron Singh, MD1, Marianne E. Pavel, MD2, Jonathan Strosberg, MD3, Lida Bubuteishvili-Pacaud, MD4, Evgeny Degtyarev, MSc4, Maureen P. Neary, PhD5, Matthias Hunger, PhD6, Jennifer Eriksson, MSc7, Nicola Fazio, MD8, Matthew Kulke, MD9 and James C. Yao, MD10, (1)Sunnybrook Health Sciences Centre, Toronto, ON, Canada, (2)CharitÚ Berlin Campus Virchow-Klinikum, Berlin, Germany, (3)Department of Medicine, Moffitt Cancer Center, Tampa, FL, (4)Novartis Pharma AG, Basel, Switzerland, (5)Novartis Pharmaceuticals Corporation, East Hanover, NJ, (6)Mapi, Munich, Germany, (7)Mapi, Stockholm, Sweden, (8)Istituto Europeo di Oncologia IRCCS, Milan, Italy, (9)Dana Farber Cancer Institute, Boston, MA, (10)University of Texas MD Anderson Cancer Center, Houston, TX
PS4-19

Asmaa El-Banna, MSc1, Jason Madan, MA, MSc, PhD1 and Ian Cree2, (1)University of Warwick, Coventry, United Kingdom, (2)University Hospitals Coventry and Warwickshire, Coventry, United Kingdom